Loading resource…

JAMA
Meropenem is a widely prescribed β-lactam antibiotic known for its pharmacodynamic efficacy when administered continuously. This randomized clinical trial, known as the MERCY trial, aims to determine whether continuous infusion provides better outcomes compared to intermittent dosing in terms of all-cause mortality and the emergence of drug-resistant bacteria. The findings suggest no significant difference in the primary outcomes between the two administration methods.
No account needed